HIVdent.org | Research News

PrEP at IAS 2017 / IAS Coverage
	Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents - Dapivirine Vaginal Ring Safe and Acceptable in US Adolescents - (08/07/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	An Open Label Multiple Dose Phase 1 Assessment of Long Acting Rilpivirine - Long-Acting Rilpivirine Suppresses Replication in Rectal Explants - Mark (08/07/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	One-year experience with Pre-Exposure Prophylaxis (PrEP) Implementation in France with TDF/FTC - (08/03/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Is on-demand PrEP with TDF/FTC effective among MSM with infrequent sexual intercourse? - (08/03/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy - 'PrEP missed opportunities' - (08/03/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Impact of microbiota on female genital tissue and plasma concentrations of dapivirine - (08/02/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Limited implementation of HIV pre-exposure prophylaxis among public health departments in North Carolina, United States - (08/02/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Changes in Truvada® for HIV Pre-exposure Prophylaxis Utilization in the USA: 2012-2016 - Disparities - (08/02/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Reasons for not using PrEP in a national on-line sample of U.S. men who have sex with men (MSM) - Cost, Side Effects, Access Lead Reasons for PrEP Nonuse by US MSM - (07/31/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Experiences and perceptions of PrEP among gay, MSM, and TGW in the PROUD study in England: 'Rules' of Sex, Psychological, Psychosocial Benefits - (07/31/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England - (07/31/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Long term follow up of PROUD Evidence for high continued HIV exposure and durable effectiveness of PrEP - (07/31/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Is on-demand PrEP a suitable tool for MSM who practice chemsex? Results from a sub-study of the ANRS-IPERGAY trial - Chemsex Users in IPERGAY Twice as Likely to Use As-Needed PrEP - (07/28/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	No HIV Transmissions in Gay Couples if HIV+ Partner Has Undetectable Virus - (07/27/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Impact of risk perception trajectory on PrEP and condom use among Men who have Sex with Men during the Open-Label-Extension of the ANRS-IPERGAY trial - (07/27/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-uninfected Women and Men HPTN 077 - (07/26/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Single Doses as Low as 0.5 mg of the Novel NRTTI MK-8591 Suppress HIV for At Least Seven Days - (07/26/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial - (07/24/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Safety and Efficacy of Long-Acting CAB and RPV as Two Drug IM Maintenance Therapy: LATTE-2 Week 96 Results - (07/24/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	Weekly Oral MK-8591 Protects Male Rhesus Macaques against Repeated Low Dose Intrarectal Challenge with SHIV109CP3 - (07/23/17) IAS 2017: Conference on HIV Pathogenesis Treatment and Prevention Paris, France July 23-26 2017
	A Single Monotherapy Dose of MK-8591,a Novel NRTI, Suppresses HIV for Ten Days - (02/24/16) Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA
	Long-Acting Oral and Parenteral Dosing of MK-8591 for HIV Treatment or Prophylaxis - (02/24/16) Conference on Retroviruses and Opportunistic Infections (CROI) February 22-25, 2016, Boston MA

*News Updates*
	Cellular therapies are the next big step in fight against HIV/Aids Independent Online \| August 31, 2019
	Animal activists are on the wrong side of the fight against AIDS STAT \| August 30, 2019
	Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection BusinessWire \| August 28, 2019
	Repeated semen exposure promotes host resistance to infection in preclinical HIV model EurekAlert \| August 21, 2019
	New Molecule Identified That May Further Suppress Effectively Treated HIV POZ \| August 14, 2019
	Cancer therapy returns to original target: HIV Science Magazine \| August 9, 2019
	HOPE trial: Dapivirine vaginal ring reduces HIV risk by estimated 39% Healio \| August 6, 2019
	Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV JCI \| July 22, 2019
	Johnson & Johnson Announces New Public-Private Partnership to Support First Phase 3 Efficacy Study of Janssen’s Investigational Prophylactic HIV Vaccine IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention, Mexico City, July 21-24 2019
	PrEP use high but wanes after three months among young African women NIH \| July 23, 2019
	Developing a novel HIV vaccine: DNA and recombinant proteins Science Daily \| July 23, 2019
	Duke Human Vaccine Institute receives $129 million grant for HIV/AIDS research Duke Chronicle \| July 19, 2019
	HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa New England Journal of Medicine \| July 18, 2019
	Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART) New England Journal of Medicine \| July 18, 2019
	Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana New England Journal of Medicine \| July 18, 2019
	HIV-1 Epidemic Control — Insights from Test-and-Treat Trials, Slim Abdool Karim New England Journal of Medicine \| July 18, 2019
	Acceptability and Preferences for Long-Acting Antiretroviral Formulations Among People Living with HIV infection IAPAC Adherence June 17-19 Miami
	Enlisting CRISPR in the Quest for an HIV Cure NIH \| July 16th, 2019
	Johnson & Johnson to start testing on new type of HIV vaccine in US and Europe New York Daily News \| July 13, 2019
	Consortium Led by Scripps Research Gets $129 Million for HIV/AIDS Vaccine Clinical Trials Times of San Diego \| July 10, 2019
	HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya Trials. 2019 Jul 4;20(1):396. doi: 10.1186/s13063-019-3521-2.
	HIV eliminated from the genomes of living animals Nature Communications \| June 2019
	Genotype Testing at HIV Diagnosis Provides No Benefit Infectious Disease Advisor \| June 24, 2019
	Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection Science Translational Medicine \| June 15, 2019
	AIDSinfo Updates Investigational HIV Drug Fact Sheets AIDSinfo \| June 14, 2019
	Women and Clinical Trials The New York Times \| June 14, 2019
	GSK partners with CRISPR pioneer Doudna to search for new drugs STAT News \| June 13, 2019
	Durable Control of HIV Infection in the Absence of Antiretroviral Therapy - Opportunities and Obstacles Viewpoint \| June 6, 2019
	Trump administration imposes new restrictions on fetal tissue research Washington Post \| June 5, 2019
	Statement from the Department of Health and Human Services HHS.gov \| June 5, 2019
	Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study JAMA Oncol. Published online June 2, 2019
	HIV Vaccine Awareness Day 2019 — May 18, 2019 National Institutes of Health \| May 17, 2019
	Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from ... Yahoo Finance \| May 13, 2019
	NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens - LATITUDE study compares monthly injectable antiretroviral therapy to daily oral drugs NIH \| May 9, 2019
	NIH awards will advance development of vaccines for sexually transmitted infections NIH \| May 5, 2019
	Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base Cancer. 2019 May 3. doi: 10.1002/cncr.32158
	Boston hospital receives largest philanthropic gift in history for HIV/AIDS vaccine research WCVB Boston \| April 25, 2019
	Novel antibody may suppress HIV for up to four months NIH \| April 17, 2019
	Scientists find another way HIV can hide from vaccines Yale News \| April 10, 2019
	Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019 PR Newswire \| March 28, 2019
	Aaron Diamond AIDS Research Center to Join Columbia University Columbia University \| March 20, 2019
	Curing HIV just got more complicated. Can CRISPR help? Science Magazine \| March 15, 2019
	Potential effectiveness of prophylactic HPV immunization for men who have sex with men in the Netherlands: A multi-model approach PLoS Med. 2019 Mar 4;16(3):e1002756. doi: 10.1371/journal.pmed.1002756. eCollection 2019 Mar.
	This is Not A Cure for My H.I.V. New York Times \| March 9, 2019
	One step closer to ultra-long-acting PREP? AIDS: march 2019
	New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration NATAP \| February 20th, 2019
	Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate
	HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4
	NIH Clinical Trial to Track Outcomes of Liver Transplantation from HIV-Positive Donors to HIV-Positive Recipients HIV.gov \| February 15, 2019
	Ending the HIV Epidemic: A Plan for the United States NIH \| February 7, 2019
	Study of PrEP and vaginal ring for HIV prevention begins in girls and young women NIH \| February 7, 2019
	HIV-AIDS drug could help treat Alzheimer's and other age-related diseases, Brown researchers say The Providence Journal \| February 6, 2019
	Hodgkin's lymphoma and its association with EBV and HIV infection Crit Rev Clin Lab Sci. 2018 Mar;55(2):102-114. doi: 10.1080/10408363.2017.1422692. Epub 2018 Jan 9
	Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
	Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation BMJ Open. 2019 Jan 17;9(1):e024793. doi: 10.1136/bmjopen-2018-024793.
	Heterosexual oral and anal sex in Kinshasa (D.R.Congo): Data from OKAPI prospective cohort PLoS One. 2019 Jan 16;14(1):e0210398. doi: 10.1371/journal.pone.0210398. eCollection 2019
	Incidence and Correlates of STIs among Black Men who have Sex with Men Participating in the HPTN 073 PrEP Study. Clin Infect Dis. 2019 Jan 7. doi: 10.1093/cid/ciy1141.
	Scientists achieve the first proof of concept for an HIV broadly-neutralising antibody vaccine in ... aidsmap \| January 2, 2019
	Potential of HIV-Protective Drugs Administered Via Rectal Douches Infectious Disease Advisor \| December 26, 2018
	AIDS -- an approach for targeting HIV reservoirs Eurek Alert \| December 20, 2018
	AIDS: An approach for targeting HIV reservoirs Science Daily \| December 20, 2018
	Study Determines Why Patients With HIV Have Higher Rates of Cancer AJMC.com Managed Markets Network \| December 14, 2018
	NIH to fund HIV care and prevention research in the South Healio \| December 14, 2018
	Removable PrEP implant produces high drug levels in rabbits; further studies planned aidsmap \| November 15, 2018
	Johns Hopkins researchers examine testosterone use to increase BMD in HIV-infected men EurekAlert \| December 12, 2018
	A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846-18. doi: 10.1128/AAC.01846-18
	With HIV/AIDS Research Threatened, NIH Looks For Stem-Cell Alternatives Rolling Stone \| December 11, 2018
	Uganda starts tests for long acting injectable ARVs New Vision \| November 9, 2018
	Dapivirine and Contraceptive Levels in Dual-Purpose Vaginal Ring: 14-Day Study HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
	Tenofovir Rectal Douche Provides Protective Drug Levels in MSM Colon Tissue - on-demand, behaviorally-congruent HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
	Subcutaneous TAF Implants Pass 63-Day Test in Rabbits for Long-Acting PrEP HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
	High MSM Interest in Long-Acting PrEP Regardless of Current Oral PrEP Use HIV Research for Prevention (HIVR4P), October 21-25, 2018, Madrid
	The Miami monkey cured with two antibodies aidsmap \| Oct 26, 2018
	The long tail of injectable PrEP is especially long for women aidsmap \| Oct 25, 2018

HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya

Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base

Orion Biotechnology to Present OB-002 in Vitro Potency Data at the 10th International AIDS Society HIV Science Meeting in Mexico City in July 2019

New Target for HIV Immune Therapy and Cure to be Explored by Trans-Atlantic Industry-Academia Collaboration

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

Heterosexual oral and anal sex in Kinshasa (D.R.Congo): Data from OKAPI prospective cohort